Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Hepatology (Baltimore, Md.)|December 19, 2025
Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine-cisplatin: A prospective observational cohort studySeonjeong Woo, Beodeul Kang, Sung Hwan Lee, et al.
Clinical and Molecular Hepatology|March 12, 2024
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world studyYoung Eun Chon, Dong Yun Kim, Mi Na Kim, et al.
Journal of Hepatology|August 19, 2020
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinomaChang Gon Kim, Chan Kim, Sang Eun Yoon, et al.
Palliative Medicine Reports|February 6, 2023
Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in KoreaSi Won Lee, Jung Hye Kwon, Seung-Hoon Beom, et al.
Plos One|June 8, 2018
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes studyIn Sil Choi, Mihong Choi, Ju Hyun Lee, et al.
Annals of Palliative Medicine|October 13, 2022
Performance of mid-upper arm circumference and other prognostic indices based on inflammation and nutrition in oncology outpatients: a tertiary cancer center studyYu Jung Kim, Yusuke Hiratsuka, Sang-Yeon Suh, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2020
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse eventsChanghoon Yoo, Seonggyu Byeon, Yeonghak Bang, et al.
Cancer Research and Treatment|January 8, 2026
Unplanned Readmission among Patients with Advanced Cancer on Active Treatment: Multi-Center, Retrospective StudySun Young Lee, Hong Jun Kim, Shin Hye Yoo, et al.
Nature Communications|July 10, 2025
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part BKeun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, et al.
Nature Communications|October 12, 2022
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancerChoong-Kun Lee, Sun Young Rha, Hyo Song Kim, et al.
Pageof 10